LRMR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Larimar Therapeutics Inc. (LRMR) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has positive momentum in pre-market trading, a favorable analyst rating with a raised price target, and strong positive catalysts such as the FDA Breakthrough Therapy Designation and a successful $100 million stock offering. While the company is not yet profitable, the raised funds and focus on developing its lead candidate provide a strong growth narrative for long-term investors.
The MACD is positive and expanding (0.264), indicating bullish momentum. The RSI is at 77.871, in the neutral zone but nearing overbought levels. Moving averages are converging, showing no clear trend. The stock is trading near its resistance level (R1: 5.673), with potential upside towards R2: 6.548.
FDA Breakthrough Therapy Designation for the treatment of Friedreich's ataxia.
Successful upsized public offering raising $100 million at $5 per share to fund the development of its lead candidate.
Citi raised the price target to $14 from $12 and maintains a Buy rating.
The company is not yet profitable, with a net income of -$47.71 million in Q3
High implied volatility (124.95%) and low IV rank (9), indicating potential uncertainty in the stock's price movement.
In Q3 2025, the company reported no revenue growth (0% YoY), but net income improved significantly by 207.84% YoY to -$47.71 million. EPS also improved by 154.17% YoY to -0.61. The company is still in a developmental phase with no gross margin.
Citi raised the price target for LRMR to $14 from $12 and maintains a Buy rating, signaling strong confidence in the stock's future performance.
